Trial Profile

Anlotinib plus etoposide and carboplatin as first-line treatment for extensive-stage small cell lung cancer: A single arm phase II trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Carboplatin; Cisplatin; Etoposide
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms ACTION-2

Most Recent Events

01 Nov 2022 Results assessing Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer published in the Lung Cancer
09 Aug 2022 Status changed from recruiting to completed, according to Results presented at the 2022 World Conference on Lung Cancer.
09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com